Tests intensive versus liberal phosphate targets in adults on dialysis for kidney failure
Compares two blood phosphate targets in adults with kidney failure receiving dialysis.
Plain-language title generated from the registry record
Registry title: Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
Key facts
- Where
- Bangkok, ThailandSee the site
Where in Thailand
- Ramathibodi HospitalBangkok, ThailandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The University of Queensland
- Trial code
- NCT03573089
- Record updated
- 26 August 2026
- Original description
During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested. This trial will evaluate whether compared to high levels, lowering blood phosphate levels would reduce death or major events due to heart disease, improve physical health, and be cost-effective.Read full original descriptionShow less
An Investigator-initiated, International, Multi-centre, Prospective, Randomized, Open-label, Parallel-group, Superiority, and Pragmatic Large Simple Trial (LST) to Determine Whether the Currently Recommended Strategy of Intensive Reduction of Serum Phosphate Concentration Towards the Normal Level Results in Significant Patient-centred Benefits in End-stage Kidney Disease (ESKD) Patients Receiving Dialysis.
During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested. This trial will evaluate whether compared to high levels, lowering blood phosphate levels would reduce death or major events due to heart disease, improve physical health, and be cost-effective.
Inclusion: Age ≥45 years, or Age ≥18 years with diabetes,; ESKD on haemodialysis or peritoneal dialysis, for at least 3 months,; Currently prescribed at least one phosphate-lowering medication at any dose; Able to provide informed consent.
Exclusion: Elective kidney transplantation scheduled,; Concomitant major illness / comorbidity that may result in death in the next 6 months in the view of the treating physician,; Participation in an interventional study that is likely to affect serum phosphate concentration.